About AMR Action Fund
AMR Action Fund is a venture capital firm founded in 2020. It is primarily based out of Boston, United States. As of Feb 2026, AMR Action Fund is an active investor, having invested in 12 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across Life Sciences and Enterprise Applications sectors. Most recently it participated in the $***** Series A round of Centauri Therapeutics Overall, AMR Action Fund portfolio has seen 2 IPOs and 1 acquisition, namely BiomX, Bioversys and Adaptive Phage Therapeutics. A lot of funds co-invest with AMR Action Fund, with names like Deerfield sharing a substantial percentage of its portfolio. AMR Action Fund has team of 15 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
AMR Action Fund's List of Top Investments
AMR Action Fund has a portfolio of 12 companies. Their most notable investments are in Vedanta Biosciences and TenNor Therapeutics.Their portfolio spans across United States, United Kingdom, China and 3 more locations. They have invested in Life Sciences, Enterprise Applications, across Series B, Series C and 4 more. Here is the list of top investments by AMR Action Fund:1. BiomX
Microbiome therapeutics for diseases associated with microbiome dysbiosis. The company offers its flagship 3-tier microbiome modulation platform which is an end-to-end platform to identify target bacteria causing microbiome dysbiosis, modulate the microbiome through adding or eradicating bacteria. It also has a GI tract cancer program in prototype discovery and a checkpoint inhibitor program in target discovery.
Key facts about BiomX
- Founded Year: 2015
- Location: Ness Ziona (Israel)
- Stage: Public
- Total Funding till date: $56M
- Employee Count: 104 as on Jul 01, 2024
- Investors: Deerfield, Nantahala Capital Management and 19 Others
- Latest Funding Round: Post IPO, Jan 13, 2026, $*****
- Highlight: Public
Vedanta Biosciences is developing therapeutics to treat autoimmune and inflammatory diseases. The company is developing therapeutics a proprietary consortium of regulatory T cell-inducing Clostridium bacteria in the human gut. The lead drugs developed are VE303 to treat infection caused by C. difficile (phase II), VE202 to treat inflammatory bowel diseases (phase I), VE800 for cancer immunotherapy (phase I), VE416 for food allergy (phase I), and VE707 for multi-drug resistant organisms (MDRO) (clinical trials).
Key facts about Vedanta Biosciences
- Founded Year: 2010
- Location: Cambridge (United States)
- Stage: Series E
- Total Funding till date: $350M
- Employee Count: 96 as on Mar 31, 2026
- Investors: Public Health Emergency, K2 HealthVentures and 38 Others
- Latest Funding Round: Series E, Feb 23, 2024, $*****
- Highlight: Editors' Pick
3. Bioversys
Developer of therapeutics for Antimicrobial Resistance. The company is focused on developing and commercializing antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. The company's pipeline includes BV100 for Acinetobacter baumannii and Alpibectir for tuberculosis.
Key facts about Bioversys
- Founded Year: 2008
- Location: Basel (Switzerland)
- Stage: Public
- Total Funding till date: $62.5M
- Employee Count: 22 as on Jul 01, 2024
- Investors: IMI, AMR Action Fund and 10 Others
- Latest Funding Round: Series C, Jan 05, 2023, $*****
- Highlight: Public
4. F2g
Developer of novel therapeutics for life-threatening, rare fungal infections. The company focuses on creating options for defined patient populations. It is motivated to grow, adapt, and navigate complex challenges. The company harnesses the power of science to achieve results.
Key facts about F2g
- Founded Year: 1998
- Location: Manchester (United Kingdom)
- Valuation: $*****
- Stage: Series H
- Total Funding till date: $353M
- Employee Count: 97 as on Mar 31, 2026
- Investors: Aisling Capital, Advent Life Sciences and 21 Others
- Latest Funding Round: Series H, Sep 12, 2024, $*****
- Highlight: Editors' Pick
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Key facts about Centauri Therapeutics
- Founded Year: 2014
- Location: Kent (United Kingdom)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $73M
- Employee Count: 24 as on Feb 28, 2026
- Investors: Boehringer Ingelheim Venture Fund, REPAIR Impact Fund and 32 Others
- Latest Funding Round: Series A, Feb 24, 2026, $*****
- Highlight: Editors' Pick
AMR Action Fund's Year-on-Year Investment Trends
AMR Action Fund has invested in 12 companies over the last 5 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 1 investment, while as of Feb 2026, it has made 1 investment in this year. Its most recent first time investment was in Centauri Therapeutics and most recent follow-on round was in Vedanta Biosciences.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 0 | 1 |
2024 | 4 | 1 | 5 |
2023 | 3 | 2 | 5 |
2022 | 2 | 1 | 3 |
2021 | 1 | 0 | 1 |
AMR Action Fund's Investments by Stage
AMR Action Fund has made 4 investments in Series B stage with an average round size of $61.7M, 3 investments in Series C stage with an average round size of $29.3M and 2 investments in Series E stage with an average round size of $80.3M.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series C | 3 |
Series E | 2 |
Post IPO | 1 |
Series A | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
AMR Action Fund's Investments by Sector
AMR Action Fund has a diverse portfolio, with companies operating in the Life Sciences, Sustainability Tech and Enterprise Applications. Notably, it has invested in 12 Tech companies, 10 Enterprise (B2B) companies, 1 Consumer (B2C) company and at least 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 12 |
Sustainability Tech | 11 |
Enterprise Applications | 1 |
Note: We have considered here, only first round of investments
AMR Action Fund's Investments by Geography
AMR Action Fund has made most investments in United States (6), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 6 |
United Kingdom | 2 |
China | 1 |
France | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
AMR Action Fund's recent investments
AMR Action Fund has made 1 investments in 2026 so far - Centauri Therapeutics.Here are the most recent investments by AMR Action Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 24, 2026 | United Kingdom | Series A | 5944 | - | |
Oct 16, 2025 | United States | Series B | 4383 | [+4] | |
Oct 16, 2024 | China | Series E | 8981 | ||
Sep 12, 2024 | United Kingdom | Series H | 9280 | [+8] | |
Jun 17, 2024 | United States | Series B | 9873 | [+1] |
IPOs and Publicly Listed companies in AMR Action Fund's Portfolio
2 of AMR Action Fund's portfolio companies have become public. Bioversys got listed on the SIX Swiss Exchange (SWX), in Feb 2025 at marketcap of $234M and BiomX got listed on the American Stock Exchange (NYSEAMERICAN) at marketcap of $87.5M.Here are AMR Action Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 07, 2025 | Jun 08, 2022 | Series C | 6211 | |
Aug 02, 2019 | Mar 06, 2024 | Post IPO | 6376 |
Acquired companies in AMR Action Fund's Portfolio
1 company from AMR Action Fund's portfolio has been acquired. The most recent acquisition were Adaptive Phage Therapeutics in Mar 2024 by BiomX.Here are AMR Action Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 06, 2024 | May 11, 2021 | Series B | 2484 |
Team profile of AMR Action Fund
AMR Action Fund has a team of 15 members including 5 Partners and 3 Principals located in United States and Switzerland. AMR Action Fund's team does not sit on the board of any company as of now.Here is a list of top team members in AMR Action Fund:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Worcester | - | - | |
Partner | Boston | - | ||
Partner | Geneva | - | ||
Partner | Switzerland | - | - | |
Partner | Danville | - | - | |
Principal | Boston | - | ||
Principal | Boston | - | ||
Principal | Boston | - |
Co-investors of AMR Action Fund
Over the past 5 years, 148 investors have co-invested in AMR Action Fund's portfolio companies. This includes funds and angels.
- Invested before AMR Action Fund: CARB-X, Seventure Partners and 109 others have invested in rounds before AMR Action Fund. There are 6 companies where CARB-X has invested before AMR Action Fund and 2 companies where Seventure Partners has invested before AMR Action Fund.
- Top Co-investors of AMR Action Fund: 31 investors entered a company along with AMR Action Fund. These include investors like Deerfield (2 companies).
- Invested after AMR Action Fund: A total of 6 investors have invested in AMR Action Fund's portfolio after their investments. Top Investors include Deerfield (1 company), Colorcon (1 company) and Lilly (1 company).
Recent News related to AMR Action Fund
•
£6m support takes Cheshire bio company’s Series A round to £30mTheBusinessDesk.com•Feb 24, 2026•Centauri Therapeutics, AMR Action Fund, Centauri Health Solutions
•
Latham Advises erad on US$33 Million Debt FinancingLegal Desire•Nov 14, 2025•Stride Ventures, Latham & Watkins, Erad, AMR Action Fund and 2 others
•
Peter Thiel-backed Peptilogics raises $78M for prosthetic joint infection programEndpoints•Oct 16, 2025•Peptilogics, Presight Capital, Founders Fund, Beyond Venture Partners and 5 others
•
•
F2G inks $100M Series H for another shot at treating fungal infectionsEndPoints News•Sep 12, 2024•F2g, AMR Action Fund, ICG
•
•
Antabio SAS raises €25 m in Series B financingEuropean Biotechnology•Dec 12, 2023•Antabio, AMR Action Fund, European Innovation Council, BNP Paribas Developpement and 2 others
•
Merck Collaborates to Address Antimicrobial ResistanceContract Pharma•Oct 05, 2023•Merck, AMR Action Fund
•
Pattern Bioscience Closes $28.7M Series C Financing Round360Dx•Apr 27, 2023•Illumina Ventures, AMR Action Fund, Dale Shaw, Pattern Bioscience and 2 others
•
Vedanta Biosciences Raises $106.5M in FundingFinSMEs•Apr 25, 2023•Vedanta Biosciences, AXA Investment Managers, AMR Action Fund, Gates Foundation and 14 others
